Detailed Information
Cited 2 time in 
Cited 0 time in 
Cited 0 time in
Metadata Downloads
Brigatinib (BRG) in patients (pts) with crizotinib (CRZ)-refractory ALK plus non-small cell lung cancer (NSCLC) and brain metastases in the pivotal randomized phase 2 ALTA trial
- Authors
- Ou, SHI[Ou, Sai-Hong Ignatius]; Tiseo, M[Tiseo, Marcella]; Camidge, DR[Camidge, D. Ross]; Ahn, MJ[Ahn, Myung-Ju]; Huber, RM[Huber, Rudolf M.]; Hochmair, MJ[Hochmair, Maximilian J.]; Kim, SW[Kim, Sang-We]; West, HJ[West, Howard Jack]; Reckamp, KL[Reckamp, Karen L.]; Molina, JR[Molina, Julian R.]; Liu, G[Liu, Geoffrey]; Delmonte, A[Delmonte, Angelo]; Ramirez, SV[Ramirez, Santiago Viteri]; Bearz, A[Bearz, Alessandra]; Summers, YJ[Summers, Yvonne J.]; Reichmann, W[Reichmann, William]; Kerstein, D[Kerstein, David]; Gettinger, SN[Gettinger, Scott N.]; Kim, DW[Kim, Dong-Wan]
- Issue Date
- 20-May-2017
- Publisher
- AMER SOC CLINICAL ONCOLOGY
- Citation
- JOURNAL OF CLINICAL ONCOLOGY, v.35
- Indexed
- SCIE
SCOPUS
- Journal Title
- JOURNAL OF CLINICAL ONCOLOGY
- Volume
- 35
- ISSN
- 0732-183X
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.